伊莱克特拉治疗
估值 各估值倍数与自身5年区间的对比
同业对比 Biotechnology
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 伊莱克特拉治疗 (ETRA) | 534.63M | -5.62 | -2.44 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 126.66B | 29.11 | 6.26 | 0.00% |
| Moderna (MRNA) | 87.04B | -27.32 | 12.87 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 81.41B | 19.57 | 2.57 | 0.46% |
| argenx SE (ARGX) | 51.51B | 31.21 | 6.12 | 0.00% |
| BeiGene (ONC) | 41.96B | 65.32 | 8.11 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算41.1%。
合理价值
Electra Therapeutics Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 26% discount to our quantitative fair value estimate of $12.35 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
经济护城河
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run.
作者：Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
伊莱克特拉治疗 讨论区 0 条评论